Hope for DCM Therapies: Tenaya Therapeutics
Thursday, October 22, 2020 from 6:00-7:00PM ET
Hosted by Tenaya Therapeutics and the DCM Foundation
The DCM Foundation and Tenaya Therapeutics look forward to sharing important science and research that Tenaya is conducting, which is providing hope for patients and families impacted by heart disease, including those with DCM.
Learning objectives for this webinar include:
- Learn more about the innovative science Tenaya Therapeutics is advancing for genetic and non-genetic forms of heart disease.
- Hope for DCM: Gene therapies, regenerative medicines, and small molecules
- Learn more about the specific research Tenaya Therapeutics is doing on genetic DCM, including in collaboration with Dr. Ray Hershberger and the DCM Consortium, and how this contributes to the vision of personalized medicine for DCM
- Find out how individuals and families affected by DCM can get involved at all stages of drug development
- Opportunity for interactive and honest Q&A with Tenaya Therapeutics leadership
Please share the details of this webinar with individuals impacted by DCM and their families.
Whittemore Tingley, MD, PhD
Chief Medical Officer
Dr. Whittemore Tingley joined Tenaya Therapeutics as Chief Medical Officer in December 2018. Previously he served at Cytokinetics as Vice President of Clinical Development, Cardiology, and at Genentech as Therapeutic Area Lead for Cardiovascular and Metabolism Research and Early Development. Between 2009 and 2017, he held Medical Director and Group Medical Director roles with increasing responsibility at Genentech and Roche. Whit formerly was Adjunct Associate Professor of Medicine in the Cardiology Division at the University of California, San Francisco and cared for patients as an Attending Cardiologist in the UCSF Cardiology Faculty Practice.
Whit earned an A.B. degree from Brown University and M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine. He completed internship and residency programs at the Johns Hopkins Hospital, cardiology fellowship at UCSF and post-doctoral research at the Gladstone Institutes.
Greg Ruf is the President and Founder of the DCM Foundation. In 2014, Greg was diagnosed with DCM with an extremely weakened heart muscle and conduction system disease requiring a pacemaker. Nine of Greg’s family members have been identified with gene mutations known to cause DCM. Over the past 31 years, he has launched and financed seven separate entrepreneurial ventures, six of which have been financially successful.